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Abstract. Requirements about the quality of medical guidelines can be
represented using schemata borrowed from the theory of abductive diag-
nosis, using temporal logic to model the time-oriented aspects expressed
in a guideline. In this paper, we investigate how this approach can be
mapped to the facilities offered by a theorem proving system for pro-
gram verification, KIV. It is shown that the reasoning that is required
for checking the quality of a guideline can be mapped to such theorem-
proving facilities. The medical quality of an actual guideline concerning
diabetes mellitus 2 is investigated in this way, and some problems dis-
covered are discussed.
1 Introduction
Health-care is becoming more and more complicated at an astonishing rate. On
the one hand, the number of different patient management options has risen
considerably during the last couple of decades, whereas, on the other hand,
medical doctors are expected to take decisions balancing benefits for the patient
against financial costs. There is a growing trend within the medical profession
to believe that clinical decision-making should be based as much as possible
on sound scientific evidence; this has become known as evidence-based medicine
[12]. Evidence-based medicine has given a major impetus to the development of
guidelines, documents offering a detailed description of steps that must be taken
and considerations that must be taken into account by health-care professionals
in managing a disease in a patient to avoid substandard practices or outcomes.
Their general aim is to promote standards of medical care.
Researchers in artificial intelligence (AI) have picked up on these develop-
ments, and some of them, for example in the Asgaard project [10], are involved
in the design of computer-oriented languages, tools and systems that support
the design and deployment of medical guidelines. AI researchers see guidelines
as good real-world examples of highly structured, systematic documents that are
amenable to formalisation.
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There are two approaches to checking the quality of medical guidelines: (1)
the object-level approach amounts to translating a guideline to a formal language,
such as Asbru [10], and next applying techniques from program verification to
the resulting representation in establishing partial or total correctness; (2) the
meta-level approach, which consists of formalising general properties to which a
guideline should comply, and then investigating whether this is the case. Here
we are concerned with the meta-level approach to guideline-quality checking.
For example, a good-quality medical guideline regarding treatment of a disor-
der should preclude the prescription of redundant drugs, or advise against the
prescription of treatment that is less effective than some alternative. Carrying
out such checks could be valuable, in particular during the process of designing
medical guidelines.
In this paper we explore the route from an informal medical guideline to its
logical formalisation and verification. Previously we have shown that the theory
of abductive diagnosis can be taken as a foundation for the formalisation of
quality criteria of a medical guideline [7]. In this paper we study the use of
logical deduction using temporal logic to formally establish whether a guideline
fulfils particular quality requirements. For this purpose use was made of the
theorem prover KIV [1]. This is a somewhat unusual approach, as KIV and its
underlying logics are especially targeted at the verification of parallel programs,
whereas here we are concerned with a type of reasoning that comes from AI.
The paper is organised as follows. In the next section, we start by explaining
what medical guidelines are, and a method for formalising guidelines by tempo-
ral logic, including the logic supported by the theorem prover KIV, are briefly
reviewed. In Section 3 the formalisation of guideline quality using a meta-level
schema which comes from the theory of abductive diagnosis is described. The
guideline on the management of diabetes mellitus type 2 that has been used in
the case study is given attention to in Section 4 and a formalisation of this is
given. The approach to checking the quality of this guideline using the deductive
machinery offered by KIV is presented in Section 5. Finally, Section 6 discusses
what has been achieved and suggests some future plans for research.
2 Preliminaries
2.1 The Design of Medical Guidelines
The design of a medical guideline is far from easy. Firstly, the gathering and
classification of the scientific evidence underlying and justifying the recommen-
dations mentioned in a guideline is time consuming, and requires considerable
expertise in the medical field concerned. Secondly, medical guidelines are very
detailed, and making sure that all the information contained in the guideline
is complete for the guideline’s purpose, and based on sound medical principles
is hard work. An example of a tiny portion of a guideline is shown in Fig. 1;
it is part of the guideline for general practitioners about the treatment of dia-
betes mellitus type 2. This guideline fragment is used in this paper as a running
example.
– Step 1: diet
– Step 2: if Quetelet Index (QI) ≤ 24, prescribe a sulfonylurea drug; otherwise,
prescribe a biguanide drug
– Step 3: combine a sulfonylurea drug and biguanide (replace one of these by a
α-glucosidase inhibitor if side-effects occur)
– Step 4: one of the following:
• oral antidiabetics and insulin
• only insulin
Fig. 1. Tiny fragment of a clinical guideline on the management of diabetes mellitus
type 2. If one of the steps k = 1, 2, 3 is ineffective, the management moves to step k+1.
One way to use formal methods in the context of guidelines is to automat-
ically verify whether a medical guideline fulfils particular properties, such as
whether it complies with quality indicators as proposed by health-care profes-
sionals [8]. For example, using particular patient assumptions such as that after
treatment the levels of a substance are dangerously high or low, it is possible to
check whether this situation does or does not violate the guideline. However, ver-
ifying the effects of treatment as well as examining whether a developed medical
guideline complies with global criteria, such as that it avoids the prescription of
redundant drugs, or the request of tests that are superfluous, is difficult to impos-
sible if only the guideline text is available. Thus, the capability to check whether
a guideline fulfils particular medical objectives may require the availability of
more medical knowledge than is actually specified in a medical guideline, i.e.
background knowledge is required.
Table 1. Used temporal operators; t stands for a time instance.
Notation Interpretation Formal semantics
Hϕ ϕ has always been true in the past t  Hϕ⇔ ∀t′ < t : t′  ϕ
Gϕ ϕ is true at all future times t  Gϕ⇔ ∀t′ ≥ t : t′  ϕ
2.2 Using Temporal Logic for Guideline Representation
As medical management is a time-oriented process, diagnostic and treatment
actions described in guidelines are performed in a temporal setting. It has been
shown previously that the step-wise, possibly iterative, execution of a guideline,
such as the example in Fig. 1, can be described precisely by means of temporal
logic [8]. This is a modal logic, where relationships between worlds in the usual
possible-world semantics of modal logic is understood as time order, i.e. formulae
are interpreted in a temporal structure F = (T, <, I). We will assume that the
progression in time is linear, i.e. < is a strict linear order. For the representation
of the medical knowledge involved it appeared to be sufficient to use rather ab-
stract temporal operators as proposed in literature [7]. The language of standard
logic, with equality and unique names assumption, is augmented with the modal
operators G, H, P and F, where the temporal semantics of the first two operators
is defined in Table 1. The last two operators are simply defined in terms of the
first two operators:
 Pϕ↔ ¬H¬ϕ (somewhere in the past)
 Fϕ↔ ¬G¬ϕ (somewhere in the future)
This logic offers the right abstraction level to cope with the nature of the tem-
poral knowledge in medical guidelines required for our purposes. However, more
fine-grained temporal operators can be added if needed. For a full axiomatisation
of this logic, see Ref. [11].
Even though this logic was shown to be suitable for representation purposes,
we had to map it to the temporal logic underlying KIV, which we had chosen
as the system to be used for formal verification. As a consequence, in the next
section, this temporal logic is briefly described. The mapping is given in Section
5.1.
2.3 Temporal Logic in KIV
The interactive theorem prover KIV offers support for future-time linear tempo-
ral logic [2]. Reactive systems can be described in KIV by means of state-charts
or parallel programs; here we use parallel programs. A state of a system can be
described by first-order logic. Furthermore, static variables v, which have the
same values at each time point, are distinguished from dynamic variables V .
A specialty of KIV is the use of primed and double-primed variables: a primed
variable V ′ represents the value of this variable after a system transition, the
double-primed variable V ′′ is interpreted as the value after an environment tran-
sition. System and environment transitions alternate, with V ′′ being equal to V
in the successive state.
The supported future-time temporal operators include the operators from
Table 2, where succ(t) is the set of zero or one successors of t. Note that all
formulae are interpreted with respect to the first point of time. Let e denote an
arbitrary (first-order) expression, then constructs for parallel programs include:
V := e (assignments), if ψ then φ1 else φ2 (conditionals), while ψ do φ (loops),
var V = e in φ (local variables), patom φ end (atomic execution), φ1
f
φ2
(interleaved execution), and p(e, V ) (call to procedure p with value parameters e
and var parameters V ).
A temporal logic property for a parallel program is verified in KIV by sym-
bolic execution with induction. Hence, there is a major difference between the
temporal logic underlying KIV and the one discussed in the previous section,
both in intention and in expressive power.
3 Application to Medical Knowledge
It is assumed that two types of knowledge are involved in detecting the violation
of good medical practice:
Table 2. Used temporal operators; t stands for a time instance.
Notation Interpretation Formal semantics
2 ϕ ϕ will always be true t  2 ϕ⇔ ∀t′ ≥ t : t′  ϕ
3 ϕ ϕ will eventually be true t  3 ϕ⇔ ∃t′ ≥ t : t′  ϕ
ϕ until ψ ϕ holds until ψ eventually holds t  ϕ until ψ
⇔ ∃ t′ ≥ t : t′  ψ
∧ ∀ t ≤ t′′ < t′ : t′′  ϕ
ϕ unless ψ ϕ holds unless ψ holds t  ϕ unless ψ
⇔ ∀ t′ ≥ t : t′  ϕ
∨ ∃ t ≤ t′′ ≤ t′ : t′′  ψ
◦ ϕ execution does not terminate and
the next state satisfies ϕ
t  ◦ ϕ⇔ ∃ t′ ∈ succ(t) : t′  ϕ
• ϕ either execution terminates or the
next state satisfies ϕ
t  ◦ ϕ⇔ ∀ t′ ∈ succ(t) : t′  ϕ
last the current state is the last t  last ⇔ succ(t) = ∅
– Knowledge concerning the (patho)physiological mechanisms underlying the
disease, and the way treatment influences these mechanisms. The knowledge
involved could be causal in nature, and is an example of object-knowledge.
– Knowledge concerning good practice in treatment selection; this is meta-
knowledge.
Below we present some ideas on how such knowledge may be formalised using
temporal logic (cf. [5] for earlier work).
We are interested in the prescription of drugs, taking into account their mode
of action. Abstracting from the dynamics of their pharmacokinetics, this can be
formalised in logic as follows:
(G d ∧ r) → G(m1 ∧ · · · ∧mn)
where d is the name of a drug or possibly of a group of drugs indicated by a
predicate symbol (e.g. SU(x), where x is universally quantified and ‘SU’ stands
for sulfonylurea drugs, such as Tolbutamid), r is a (possibly negative or empty)
requirement for the drug to take effect, and mk is a mode of action, such as
decrease of release of glucose from the liver, which holds at all future times.
The modes of action mk can be combined, together with an intention n
(achieving normoglycaemia, i.e. normal blood glucose levels, for example), a
particular patient condition c, and requirements rj for the modes of action to be
effective:
(Gmi1 ∧ · · · ∧ Gmim ∧ r1 ∧ · · · ∧ rp ∧ Hc) → Gn
Good practice medicine can then be formalised as follows. Let B be background
knowledge, T ⊆ {d1, . . . , dp} be a set of drugs, C a collection of patient condi-
tions, R a collection of requirements, and N a collection of intentions which the
physician has to achieve. A set of drugs T is a treatment according to the theory
of abductive reasoning if [9, 6]:
(M1) B ∪ GT ∪ C ∪ R 2 ⊥ (the drugs do not have contradictory effects), and
(M2) B ∪GT ∪C ∪R  N (the drugs handle all the patient problems intended
to be managed)
If in addition to (1) and (2) condition
(M3) Oϕ(T ) holds, where Oϕ is a meta-predicate standing for an optimality
criterion or combination of optimality criteria ϕ,
then the treatment is said to be in accordance with good-practice medicine. A
typical example of this is subset minimality O⊂:
O⊂(T ) ≡ ∀T
′ ⊂ T : T ′ is not a treatment according to (1) and (2)
i.e. the minimum number of effective drugs are being prescribed. For example,
if {d1, d2, d3} is a treatment that satisfies condition (3) in addition to (1) and
(2), then the subsets {d1, d2}, {d2, d3}, {d1}, and so on, do not satisfy conditions
(1) and (2). In the context of abductive reasoning, subset minimality is often
used in order to distinguish between various solutions; it is also referred to in
literature as Occam’s razor. Another definition of the meta-predicate Oϕ is in
terms of minimal cost Oc:
Oc(T ) ≡ ∀T
′,with T ′ a treatment: c(T ′) ≥ c(T )
where c(T ) =
∑
d∈T cost(d); combining the two definitions also makes sense. For
example, one could come up with a definition of O⊂,c that among two subset-
minimal treatments selects the one that is the cheapest in financial or ethical
sense.
4 Management of Diabetes Mellitus Type 2
4.1 Diabetes Type 2 Background Knowledge
It is well known that diabetes type 2 is a very complicated disease. Here we focus
on the derangement of glucose metabolism in diabetic patients; however, even
that is nontrivial. To support non-expert medical doctors in the management of
this complicated disease in patients, access to a guideline is really essential.
One would expect that as this disorder is so complicated, the diabetes mellitus
type 2 guideline is also complicated. This, however, is not the case, as may
already be apparent from the guideline fragment shown in Fig. 1. This indicates
that much of the knowledge concerning diabetes mellitus type 2 is missing from
the guideline, and that without this background knowledge it will be impossible
to spot the sort of flaws we are after. Hence, the conclusion is that a deeper
biological analysis is required, the results of which are presented below.
The protein hormone insulin, which is produced by the B cells in the Langer-
hans islets of the pancreas, has the following major effects:
– it increases the uptake of glucose by the liver, where it is stored as glycogen,
and inhibits the release of glucose from the liver;
– it increases the uptake of glucose by insulin-dependent tissues, such as muscle
and adipose tissue.
At some stage in the natural history of diabetes mellitus type 2, the level of glu-
cose in the blood is too high (hyperglycaemia) due to the decreased production
of insulin by the B cells.
Treatment of diabetes type 2 consists of:
– Use of sulfonylurea (SU) drugs, such as tolbutamid. These drugs stimulate
the B cells in producing more insulin, and if the cells are not completely ex-
hausted, the hyperglycaemia can thus be reverted to normoglycaemia (nor-
mal blood glucose levels).
– Use of biguanides (BG), such as metformin. These drugs inhibit the release
of glucose from the liver.
– Use of α-glucosidase inhibitors. These drugs inhibit (or delay) the absorp-
tion of glucose from the intestines. We omit considering these drugs in the
following, as they are only prescribed when treatment side-effects occur.
– Injection of insulin. This is the ultimate, causal treatment.
The background knowledge concerning the (patho)physiology of the glucose
metabolism as summarised above is formalised using temporal logic, and kept
as simple as possible. The specification is denoted by BDM2:
(1) G Drug(insulin) → G (uptake(liver, glucose) = up ∧
uptake(peripheral-tissues, glucose) = up)
(2) G(uptake(liver, glucose) = up → release(liver, glucose) = down)
(3) (G Drug(SU) ∧ ¬capacity(B-cells, insulin) = exhausted) →
G secretion(B-cells, insulin) = up
(4) G Drug(BG) → G release(liver, glucose) = down
(5) (Gsecretion(B-cell, insulin) = up ∧
capacity(B-cells, insulin) = subnormal ∧
QI ≤ 27 ∧ HCondition(hyperglycaemia))
→ G Condition(normoglycaemia)
(6) (Grelease(liver, glucose) = down ∧
capacity(B-cells, insulin) = subnormal ∧
QI > 27 ∧ HCondition(hyperglycaemia))
→ G Condition(normoglycaemia)
(7) ((Grelease(liver, glucose) = down ∨
Guptake(peripheral-tissues, glucose) = up) ∧
capacity(B-cells, insulin) = nearly-exhausted ∧
Gsecretion(B-cells, insulin) = up ∧
H Condition(hyperglycaemia))
→ G Condition(normoglycaemia)
(8) (Guptake(liver, glucose) = up ∧
Guptake(peripheral-tissues, glucose) = up) ∧
capacity(B-cells, insulin) = exhausted ∧
HCondition(hyperglycaemia))
→ G(Condition(normoglycaemia) ∨ Condition(hypoglycaemia))
(9) (Condition(normoglycaemia) ⊕ Condition(hypoglycaemia)
⊕ Condition(hyperglycaemia))
where ⊕ stands for the exclusive OR. Note that when the B-cells are exhausted,
increased uptake of glucose by the tissues may not only result in normoglycaemia
but also in hypoglycaemia (something not mentioned in the guideline).
4.2 Quality Check
As insulin can only be administered by injection, in contrast to the other drugs
which are normally taken orally, doctors prefer to delay prescribing insulin as
long as possible. Thus, the treatment part of the diabetes type 2 guideline men-
tions that one should start with prescribing oral antidiabetics (SU or BG, cf. Fig.
1). Two of these can also be combined if taking only one has insufficient glucose-
level lowering effect. If treatment is still unsatisfactory, the guideline suggests
to: (1) either add insulin, or (2) stop with the oral antidiabetics entirely and to
start with insulin.
The consequences of various treatment options were examined using the
method introduced in Section 3. Hypothetical patients for whom it is the in-
tention to reach a normal level of glucose in the blood (normoglycaemia) are
considered, and treatment is selected according to the guideline fragments given
in Fig. 1:
– Consider a patient with hyperglycaemia due to nearly exhausted B-cells:
BDM2 ∪ G T ∪ {capacity(B-cells, insulin) = nearly-exhausted} ∪
{HCondition(hyperglycaemia)}  GCondition(normoglycaemia)
holds for T = {Drug(SU),Drug(BG)}, which also satisfies the minimality
condition O⊂(T ).
– Prescription of treatment T = {Drug(SU),Drug(BG),Drug(insulin)} for a
patient with exhausted B-cells, as is suggested by the guideline, yields:
BDM2 ∪ G T ∪ {capacity(B-cells, insulin) = exhausted} ∪
{HCondition(hyperglycaemia)} 
G(Condition(normoglycaemia) ∨ Condition(hypoglycaemia))
In the last case, it appears that it is possible that a patient develops hypogly-
caemia due to treatment; if this possibility is excluded, then the minimality con-
dition O⊂(T ), and also O⊂,c(T ), do not hold since insulin by itself is enough to
reach normoglycaemia. In either case, good practice medicine is violated, which
is to prescribe as few drugs as possible, taking into account costs and side-effects
of drugs. Here, three drugs are prescribed whereas only two should have been
prescribed (BG and insulin, assuming that insulin alone is too costly), and the
possible occurrence of hypoglycaemia should have been prevented.
5 Quality Checking using Symbolic Execution with
Induction
In the previous section we have seen that temporal logic can be used to formally
check a medical guideline, but so far only from a theoretical point of view. Here
we will study how such proofs can be constructed semi-automatically in terms
of symbolic execution with induction using the theorem prover KIV.
5.1 Translation to KIV
In this paper we will only discuss the translation of the constructs that were em-
ployed in the formalisation in the previous section. Firstly, the universal quan-
tification of the axioms over all points in time is made explicit. Secondly, the
modal operators have to be translated. The only modal operators that were used
were G and H. The operator G is semantically equivalent to KIV’s 2 operator.
However, KIV does not support past-time operators, but as Gabbay et al. have
shown [4], it is possible to translate any temporal formula with past-time op-
erators to an equivalent temporal formula with only future-time operators that
includes ‘until’. This implies that after translation it is possible, at least in prin-
ciple, to verify the temporal formulas introduced in sections 3 and 4. Axioms
hold over all points in time of which the the ones with past-time formulas are of
the following fixed form (see section 3):
(ϕ ∧ H Condition(hyperglycaemia)) → ψ
We can rewrite this semantically and obtain a pure future-time formula, i.e. a
formula with only future-time operators, as follows:
∀t : t  (ϕ ∧ H Condition(hyperglycaemia)) → ψ
⇔ ∀t : t  (ϕ→ ψ) ∨ ¬H Condition(hyperglycaemia))
⇔ ∀t : t  ϕ→ ψ or t 2 H Condition(hyperglycaemia))
⇔ ∀t : t  ϕ→ ψ or¬∀t′ < t : t′  Condition(hyperglycaemia)
⇔ ¬∃t : t  ¬(ϕ→ ψ) and ∀t′ < t : t′  Condition(hyperglycaemia)
⇔ ¬ (Condition(hyperglycaemia) until ¬ (φ→ ψ))
5.2 Specification in KIV
In KIV datatypes are expressed in a many-sorted algebra with possibilities for
parameterisation, allowing the creation of specific sorts by defining constraints
on the parameters. The sorts with associated data elements required to create a
specification of the domain of diabetes mellitus type 2 are listed in Table 3.
In KIV, functions and predicates are static, i.e. they do not change over time.
Therefore, for the formalisation in KIV functions and predicates were mapped
to dynamic variables. For example, secretion(B-cells, insulin) was mapped to a
dynamic variable named BsecretionI. Since variables in axioms of algebraic
specifications are universally quantified, a procedure with name ‘patient’ was
used to bind these variables. This gives each relevant variable a context and
prohibits instantiations of axioms with variables that have different names.
Table 3. Data specifications.
Specification Data elements
capacity exhausted, nearly-exhausted, subnormal
condition hyperglycaemia, hypoglycaemia, normoglycaemia
updown up, down
drug SU, BG, glucosidase, insulin
setdrugs set of elements of sort drug
setsetdrugs set of elements of sort setdrugs
The axioms (3), (4) and (7) were selected and translated to KIV’s syntax as
indicated in Section 5.1. In addition, a number of variables were primed to deal
with the consistency condition mentioned in Section 3, as will be discussed in
Section 5.4. This yielded the following three sequents, denoted by A:
[patient(; Drugs, Condition, UptakeLG, UptakePG, ReleaseLG
BcapacityI, BsecretionI, QI)] `
2 (((2 SU ∈ Drugs) ∧ BcapacityI 6= exhausted) → 2 BsecretionI′ = up);
[patient(; Drugs, Condition, UptakeLG, UptakePG, ReleaseLG
BcapacityI, BsecretionI, QI)] `
2 ((2 BG ∈ Drugs) → (2 ReleaseLG′ = down));
[patient(; Drugs, Condition, UptakeLG, UptakePG, ReleaseLG
BcapacityI, BsecretionI, QI)] `
¬(Condition = hyperglycaemia until
¬((((2 ReleaseLG′ = down) ∨ (2 UptakePG = up))
∧(BcapacityI = nearly-exhausted) ∧ 2 BsecretionI′ = up)
→ (2 Condition′ = normoglycaemia)));
Now define B′DM2 as the conjunction of the right-hand-sides of A. We will show
how the meta-level properties follow from these right-hand-sides. The procedure
patient only acts as a placeholder.
5.3 Proof
Again, consider a patient with hyperglycaemia due to nearly exhausted B-cells
and T = {Drug(SU),Drug(BG)}. The following sequent, which corresponds to
condition M2 from section 3, was proven by KIV in about 50 steps:
[patient(; Drugs, Condition, UptakeLG, UptakePG, ReleaseLG
BcapacityI, BsecretionI, QI)]
` ¬(Condition = hyperglycaemia until
¬(((2 Drug = {SU, BG}) ∧ BcapacityI = nearly-exhausted)
→ (2 Condition′ = normoglycaemia)));
The proof relies on the fact that the axioms can be inserted with the appro-
priate (program-)variables, after which the patient procedure can be removed
from the sequent and the real work starts. Hence, the consequent of the sequent
is deduced from the axioms B′DM2. This yields:
B′DM2 ` ¬(Condition = hyperglycaemia until
¬(((2 Drug = {SU, BG}) ∧ BcapacityI = nearly-exhausted)
→ (2 Condition′ = normoglycaemia)));
An outline of this proof follows. The proof obligation Γ ` ∆, ¬(ϕ until ψ)
is equivalent to Γ, ϕ until ψ ` ∆. The sequent is proved by induction over
the number of steps it takes to satisfy ψ. For this, introduce a fresh dynamic
variable N and generalise the sequent to (N = N ′′ + 1 ∧ φ) until ψ, Γ ` ∆.
The equation N = N ′′ + 1 ensures that N decreases in each step. Now, we can
perform induction with induction term N which yields
(N = N ′′ + 1 ∧ φ) until ψ, Γ, N = n, 2(N < n→ IndHyp) ` ∆
where IndHyp = ((N = N ′′+1∧φ) until ψ)∧
∧
Γ →
∨
∆ and n is a new static
variable. We move to the next state by symbolically executing the temporal
formulae. For example,
φ until ψ ⇔ ψ ∨ (φ ∧ ◦(φ until ψ))
is used to execute the until operator. In this case, the induction hypothesis can
be applied in all possible successive states.
5.4 Disproofs
The final part of this section we will show disproofs of properties that do not
follow from B′DM2 by using program verification techniques. In the previous
section we reasoned with the given axioms A, but here we use a more extensive
implementation of the patient procedure as shown in Fig. 5.4, which not only
binds variables, but implements part of the therapeutic reasoning.
Now define the theory
M = {[patient(...)]} ∪
⋃
x6=Drugs
{2 x′ = x′′}
where the last term denotes that variables, except for Drugs, are not altered by
the environment, but only by the program itself. In about 400 steps using KIV it
was proved that M ` B′DM2, which implies M  B
′
DM2 assuming KIV is sound.
From this and the fact that M is consistent (since a program is consistent and
the environment is not altered), we have shown that B′DM2 2 ⊥ and therefore
condition M1. The number of steps shows that this proof was significantly harder.
The reason is that in many cases an invariant could only be defined after an initial
symbolic execution. This caused an explosion of states that had to be considered.
Furthermore, the invariants that had to be formulated were less straightforward.
Now showing that this set of drugs is a minimal treatment (condition M3),
as discussed in Section 4, we construct for all T ′ ∈ ℘{SU,BG}, T ′ 6= {SU,BG}:
MT ′ = M ∪ {2 Drugs
′ = Drugs′′, Condition = hyperglycaemia,
BsecretionI = down, BcapacityI = nearly-exhausted,
ReleaseLG = up, UptakePG = down, Drugs = T ′}
patient(var Drugs, Condition, UptakeLG, UptakePG,
ReleaseLG, BcapacityI, BsecretionI, QI)
begin
var oncebcapi = false, hchyper = true, nownormal = false in
while true do
patom
if SU ∈ Drugs ∧ (BcapacityI 6= exhausted ∨ oncebcapi) then
begin
BsecretionI := up;
oncebcapi := true
end;
if BG ∈ Drugs then ReleaseLG := down;
if (ReleaseLG = down ∨ UptakePG = up) ∧ BsecretionI = up ∧
((Bcapacity = nearly-exhausted ∧ hchyper) ∨ nownormal) then
begin
nownormal := true;
hchyper := false;
Condition := normoglycaemia
end
end
end
Fig. 2. Declaration of the patient procedure.
Again, MT ′ is consistent. It was proved in about 25 steps with KIV that:
MT ′ ` (Condition = hyperglycaemia until
¬(((2 Drugs = T ′) ∧ BcapacityI = nearly-exhausted)
→ (2 Condition′ = normoglycaemia)));
Because of monotony of temporal logic and M  B′DM2, we have MT ′  B
′
DM2.
Since MT ′ is consistent, we can conclude:
B′DM2 2 ¬(Condition = hyperglycaemia until
¬(((2 Drugs = T ′) ∧ BcapacityI = nearly-exhausted)
→ (2 Condition′ = normoglycaemia)));
Hence, T = {Drug(SU),Drug(BG)} is a minimal treatment. As one might ex-
pect, it shows that after the construction of the appropriate countermodel, dis-
proofs are fairly easy.
6 Discussion
The quality of guideline design is for the largest part based on its compliance
with specific treatment aims and global requirements. To this purpose, use was
made of the theory of abductive, diagnostic reasoning, i.e. we proposed to diag-
nose potential problems with a guideline using logical abduction [6, 9]. This is a
meta-level characterisation of the quality of a medical guideline. What was diag-
nosed were problems in the relationship between medical knowledge, suggested
treatment actions in the guideline text and treatment effects; this is different
from traditional abductive diagnosis, where observed findings are explained in
terms of diagnostic hypotheses. This method allows us to examine fragments of
a guideline and to prove properties of those fragments.
In this paper, we have made use of the interactive theorem prover KIV [1] to
actually quality check a medical guideline using the theory of quality of guide-
lines developed previously [7]. This complements the earlier work on object-level
verification of medical guidelines using KIV [8]. About half of the steps that
were needed to complete the proofs had to be done manually. Fortunately, most
of the interactive steps were rather straightforward. We are confident that with
more specific heuristics, the proposed meta-level approach can be almost fully
automated in KIV.
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